Table of Content

1. Key Insights

2. Executive Summary of Generalized Anxiety Disorder (GAD)

3. SWOT Analysis of GAD

4. Epidemiology and Market Methodology

5. GAD: Market Overview at a Glance
5.1. Total Market Share (%) Distribution of GAD in 2017
5.2. Total Market Share (%) Distribution of GAD in 2030

6. GAD: Disease Background and Overview
6.1. Introduction
6.2. Signs and Symptoms
6.3. Risk Factors and Causes
6.4. Pathophysiology
6.5. Diagnosis
6.6. Screening Tools

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.2.1. United States
7.2.2. EU5
7.2.3. Japan
7.3. Epidemiology: 7MM
7.4. Total 12-Month Prevalent Cases of GAD in 7MM

8. United States
8.1. Total 12-Month Prevalent Cases of GAD in the United States
8.2. Gender-Specific Cases of GAD in the United States
8.3. Age-Specific Cases of GAD in the United States
8.4. Severity -Specific Cases of GAD in the United States
8.4.1. Children and Adolescents
8.4.2. Adults

9. EU5
9.1. Germany
9.1.1. Total 12-Month Prevalent Cases of GAD in Germany
9.1.2. Gender-Specific Cases of GAD in Germany
9.1.3. Age-Specific Cases of GAD in Germany
9.1.4. Severity -Specific Cases of GAD in Germany
9.2. France
9.2.1. Total 12-Month Prevalent Cases of GAD in France
9.2.2. Gender-Specific Cases of GAD in France
9.2.3. Age-Specific Cases of GAD in France
9.2.4. Severity -Specific Cases of GAD in France
9.3. Italy
9.3.1. Total 12-Month Prevalent Cases of GAD in Italy
9.3.2. Gender-Specific Cases of GAD in Italy
9.3.3. Age-Specific Cases of GAD in Italy
9.3.4. Severity -Specific Cases of GAD in Italy
9.4. Spain
9.4.1. Total 12-Month Prevalent Cases of GAD in Spain
9.4.2. Gender-Specific Cases of GAD in Spain
9.4.3. Age-Specific Cases of GAD in Spain
9.4.4. Severity -Specific Cases of GAD in Spain
9.5. The United Kingdom (UK)
9.5.1. Total 12-Month Prevalent Cases of GAD in the UK
9.5.2. Gender-Specific Cases of GAD in the UK
9.5.3. Age-Specific Cases of GAD in the UK
9.5.4. Severity -Specific Cases of GAD in the UK

10. Japan
10.1. Total 12-Month Prevalent Cases of GAD in Japan
10.2. Gender-Specific Cases of GAD in Japan
10.3. Age-Specific Cases of GAD in Japan
10.4. Severity -Specific Cases of GAD in Japan
10.4.1. Children and Adolescents
10.4.2. Adults

11. Current Treatment Practices: GAD
11.1. Treatment of special populations
11.2. Treatment Guidelines
11.2.1. National Institute for Health and Care Excellence (NICE): GAD Management
11.2.2. Treatment Recommendation Summary

12. Unmet Needs

13. Case Report
13.1. A Case Report of GAD and Changes in Treatment Plan Based on Patient Care Scenario: Follow up

14. Patient Journey of GAD

15. Key Endpoints in GAD Clinical Trials

16. Marketed Therapies
16.1. Marketed Therapies Key Cross

17. Emerging Therapies
17.1. Key Cross
17.2. BNC210: Bionomics
17.2.1. Product Description
17.2.2. Other Developmental Activities
17.2.3. Safety and Efficacy
17.3. PH94B: Pherin Pharmaceuticals/VistaGen Therapeutics
17.3.1. Product Description
17.3.2. Other Developmental Activities
17.3.3. Safety and Efficacy
17.4. Intuniv (Guanfacine; previously known as SPD503): Shire (acquired by Takeda Pharmaceuticals)
17.4.1. Product Description
17.4.2. Other Developmental Activities
17.4.3. Clinical Development
17.4.4. Safety and Efficacy
17.5. Troriluzole: BioHaven Pharmaceuticals
17.5.1. Product Description
17.5.2. Other Developmental Activities
17.5.3. Clinical Development
17.5.4. Safety and Efficacy

18. GAD: Seven Major Market Analysis
18.1. Key Findings
18.2. Market Outlook: 7MM
18.3. Total Market Size of GAD in 7MM
18.4. Total Market Size of GAD by Therapies in 7MM
18.5. United States
18.5.1. Total Market size of GAD in the US
18.5.2. Total Market Size of GAD by Therapies in the US
18.6. EU5
18.7. Germany
18.7.1. Total Market size of GAD in Germany
18.7.2. Total Market Size of GAD by Therapies in Germany
18.8. France
18.8.1. Total Market size of GAD in France
18.8.2. Total Market Size of GAD by Therapies in France
18.9. Italy
18.9.1. Total Market size of GAD in Italy
18.9.2. Total Market Size of GAD by Therapies in Italy
18.10. Spain
18.10.1. Total Market size of GAD in Spain
18.10.2. Total Market Size of GAD by Therapies in Spain
18.11. United Kingdom
18.11.1. Total Market size of GAD in the UK
18.11.2. Total Market Size of GAD by Therapies in the UK
18.12. Japan
18.12.1. Total Market size of GAD in Japan
18.12.2. Total Market Size of GAD by Therapies in Japan

19. Market Access and Reimbursement of GAD Therapies
19.1. NICE Recommendations
19.2. British Association of Psychopharmacology Recommendations
19.3. Access and Reimbursement of Other Therapies
19.4. Reimbursement Management

20. Market Drivers
21. Market Barriers
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight



List of Figures


Figure 1 GAD SWOT Analysis
Figure 2 Epidemiology and Market Methodology
Figure 3 Overview of GAD
Figure 4 Symptoms and Behaviors Associated with Generalized Anxiety Disorder
Figure 5 Etiology of GAD
Figure 6 Risk factors for GAD
Figure 7 Mental Disorders Screening?General Anxiety Disorder Assessment (GAD-7)
Figure 8 Mental Disorders Screening?Generalized Anxiety Disorder 2-item (GAD-2)
Figure 9 Total 12-Month Prevalent Cases of GAD in the 7MM (2017–2030)
Figure 10 Total 12-Month Prevalent Cases of GAD in the United States (2017–2030)
Figure 11 Gender-Specific Cases of GAD in the United States (2017–2030)
Figure 12 Age-Specific Cases of GAD in the United States (2017–2030)
Figure 13 Severity-Specific Cases of GAD in Children and Adolescents in the United States (2017–2030)
Figure 14 Severity-Specific Cases of GAD in Adults in the United States (2017–2030)
Figure 15 Total 12-Month Prevalent Cases of GAD in Germany (2017–2030)
Figure 16 Gender-Specific Cases of GAD in Germany (2017–2030)
Figure 17 Age-Specific Cases of GAD in Germany (2017–2030)
Figure 18 Severity-Specific Cases of GAD in Children and Adolescents in Germany (2017–2030)
Figure 19 Severity-Specific Cases of GAD in Adults in Germany (2017–2030)
Figure 20 Total 12-Month Prevalent Cases of GAD in France (2017–2030)
Figure 21 Gender-Specific Cases of GAD in France (2017–2030)
Figure 22 Age-Specific Cases of GAD in France (2017–2030)
Figure 23 Severity-Specific Cases of GAD in Children and Adolescents in France (2017–2030)
Figure 24 Severity-Specific Cases of GAD in Adults in France (2017–2030)
Figure 25 Total 12-Month Prevalent Cases of GAD in Italy (2017–2030)
Figure 26 Gender-Specific Cases of GAD in Italy (2017–2030)
Figure 27 Age-Specific Cases of GAD in Italy (2017–2030)
Figure 28 Severity-Specific Cases of GAD in Children and Adolescents in Italy (2017–2030)
Figure 29 Severity-Specific Cases of GAD in Adults in Italy (2017–2030)
Figure 30 Total 12-Month Prevalent Cases of GAD in Spain (2017–2030)
Figure 31 Gender-Specific Cases of GAD in Spain (2017–2030)
Figure 32 Age-Specific Cases of GAD in Spain (2017–2030)
Figure 33 Severity-Specific Cases of GAD in Children and Adolescents in Spain (2017–2030)
Figure 34 Severity-Specific Cases of GAD in Adults in Spain (2017–2030)
Figure 35 Total 12-Month Prevalent Cases of GAD in the UK (2017–2030)
Figure 36 Gender-Specific Cases of GAD in the UK (2017–2030)
Figure 37 Age-Specific Cases of GAD in the UK (2017–2030)
Figure 38 Severity-Specific Cases of GAD in Children and Adolescents in the UK (2017–2030)
Figure 39 Severity-Specific Cases of GAD in Adults in the UK (2017–2030)
Figure 40 Total 12-Month Prevalent Cases of GAD in Japan (2017–2030)
Figure 41 Gender-Specific Cases of GAD in Japan (2017–2030)
Figure 42 Age-Specific Cases of GAD in Japan (2017–2030)
Figure 43 Severity-Specific Cases of GAD in Children and Adolescents in Japan (2017–2030)
Figure 44 Severity-Specific Cases of GAD in Adults in Japan (2017–2030)
Figure 45 GAD Treatment Flow chart
Figure 46 Cognitive Behavioural Therapy
Figure 47 Pharmacotherapy for GAD
Figure 48 GAD Management overview
Figure 49 Unmet Needs for Generalized anxiety disorder
Figure 50 Total Market Size of GAD in 7MM in USD Million (2017-2030)
Figure 51 Total Market Size of GAD by Therapies in 7MM in USD Million (2017-2030)
Figure 52 Market size of GAD in the US (2017–2030)
Figure 53 Total Market Size of GAD by Therapies in the US, in USD Million (2017-2030)
Figure 54 Market size of GAD in Germany (2017–2030)
Figure 55 Total Market Size of GAD by Therapies in Germany, in USD Million (2017-2030)
Figure 56 Market size of GAD in France (2017–2030)
Figure 57 Total Market Size of GAD by Therapies in France, in USD Million (2017-2030)
Figure 58 Market size of GAD in Italy (2017–2030)
Figure 59 Total Market Size of GAD by Therapies in Italy, in USD Million (2017-2030)
Figure 60 Market size of GAD in Spain (2017–2030)
Figure 61 Total Market Size of GAD by Therapies in Spain, in USD Million (2017-2030)
Figure 62 Market size of GAD in the UK (2017–2030)
Figure 63 Total Market Size of GAD by Therapies in the UK, in USD Million (2017-2030)
Figure 64 Market size of GAD in Japan (2017–2030)
Figure 65 Total Market Size of GAD by Therapies in Japan, in USD Million (2017-2030)
Figure 66 Market Drivers of GAD
Figure 67 Market Barriers to GAD

 

List of Tables


Table 1 Summary of GAD Market, Epidemiology, and Key Events (2017–2030)
Table 2 “Normal” Worry vs. Generalized Anxiety Disorder
Table 3 Medical Conditions and Medications that Can Cause Anxiety
Table 4 Characteristics to define GAD in DSM-V
Table 5 Evolution of the definition of GAD in succeeding editions of the DSM and ICD
Table 6 Total 12-Month Prevalent Cases of GAD in the 7MM (2017–2030)
Table 7 Total 12-Month Prevalent Cases of GAD in the United States (2017–2030)
Table 8 Gender-Specific Cases of GAD in the United States (2017–2030)
Table 9 Age-Specific Cases of GAD in the United States (2017–2030)
Table 10 Severity-Specific Cases of GAD in Children and Adolescents in the United States (2017–2030)
Table 11 Severity-Specific Cases of GAD in Adults in the United States (2017–2030)
Table 12 Total 12-Month Prevalent Cases of GAD in Germany (2017–2030)
Table 13 Gender-Specific Cases of GAD in Germany (2017–2030)
Table 14 Age-Specific Cases of GAD in Germany (2017–2030)
Table 15 Severity-Specific Cases of GAD in Children and Adolescents in Germany (2017–2030)
Table 16 Severity-Specific Cases of GAD in Adults in Germany (2017–2030)
Table 17 Total 12-Month Prevalent Cases of GAD in France (2017–2030)
Table 18 Gender-Specific Cases of GAD in France (2017–2030)
Table 19 Age-Specific Cases of GAD in France (2017–2030)
Table 20 Severity-Specific Cases of GAD in Children and Adolescents in France (2017–2030)
Table 21 Severity-Specific Cases of GAD in Adults in France (2017–2030)
Table 22 Total 12-Month Prevalent Cases of GAD in Italy (2017–2030)
Table 23 Gender-Specific Cases of GAD in Italy (2017–2030)
Table 24 Age-Specific Cases of GAD in Italy (2017–2030)
Table 25 Severity-Specific Cases of GAD in Children and Adolescents in Italy (2017–2030)
Table 26 Severity-Specific Cases of GAD in Adults in Italy (2017–2030)
Table 27 Total 12-Month Prevalent Cases of GAD in Spain (2017–2030)
Table 28 Gender-Specific Cases of GAD in Spain (2017–2030)
Table 29 Age-Specific Cases of GAD in Spain (2017–2030)
Table 30 Severity-Specific Cases of GAD in Children and Adolescents in Spain (2017–2030)
Table 31 Severity-Specific Cases of GAD in Adults in Spain (2017–2030)
Table 32 Total 12-Month Prevalent Cases of GAD in the UK (2017–2030)
Table 33 Gender-Specific Cases of GAD in the UK (2017–2030)
Table 34 Age-Specific Cases of GAD in the UK (2017–2030)
Table 35 Severity-Specific Cases of GAD in Children and Adolescents in the UK (2017–2030)
Table 36 Severity-Specific Cases of GAD in Adults in the UK (2017–2030)
Table 37 Total 12-Month Prevalent Cases of GAD in Japan (2017–2030)
Table 38 Gender-Specific Cases of GAD in Japan (2017–2030)
Table 39 Age-Specific Cases of GAD in Japan (2017–2030)
Table 40 Severity-Specific Cases of GAD in Children and Adolescents in Japan (2017–2030)
Table 41 Severity-Specific Cases of GAD in Adults in Japan (2017–2030)
Table 42 Botanicals and Supplements Sometimes Used to Treat GAD and Panic Disorder
Table 43 Treatment Approach to GAD
Table 44 Treatment Recommendations Summary
Table 45 Marketed Drugs Analysis- Key cross
Table 46 Emerging Drugs Analysis-Key therapies
Table 47 Intuniv, Clinical Trial Description, 2020
Table 48 Troriluzole, Clinical Trial Description, 2020
Table 49 7MM Market Size of GAD, in USD Million (2017–2030)
Table 50 Total Market Size of GAD by Therapies in 7MM in USD Million (2017-2030)
Table 51 Total Market Size of GAD in the US, in USD Million (2017–2030)
Table 52 Total Market Size of GAD by Therapies in the US in USD Million (2017-2030)
Table 53 Total Market Size of GAD in Germany, in USD Million (2017–2030)
Table 54 Total Market Size of GAD by Therapies in Germany in USD Million (2017-2030)
Table 55 Total Market Size of GAD in France, in USD Million (2017–2030)
Table 56 Total Market Size of GAD by Therapies in France, in USD Million (2017-2030)
Table 57 Total Market Size of GAD in Italy, in USD Million (2017–2030)
Table 58 Total Market Size of GAD by Therapies in Italy in USD Million (2017-2030)
Table 59 Total Market Size of GAD in Spain, in USD Million (2017–2030)
Table 60 Total Market Size of GAD by Therapies in Spain in USD Million (2017-2030)
Table 61 Total Market Size of GAD in the UK, in USD Million (2017–2030)
Table 62 Total Market Size of GAD by Therapies in the UK in USD Million (2017-2030)
Table 63 Total Market Size of GAD in Japan, in USD Million (2017–2030)
Table 64 Total Market Size of GAD by Therapies in Japan in USD Million (2017-2030)